rian.ie - Browse

A A A

Limited By:	Institution = University College Cork;

Displaying Results 201 - 225 of 5591 on page 9 of 224

Mark

A nonlinear model of newborn EEG with nonstationary inputs (2010)

Stevenson, Nathan J.; Mesbah, Mostefa; Boylan, Geraldine B.; Colditz, Paul B.; Boashash...

Mark

A nonparametric feature for neonatal EEG seizure detection based on a representation of pseudo-periodicity (2012)

Stevenson, Nathan J.; O'Toole, John M.; Rankine, Luke J.; Boylan, Geraldine B.; Bo...

Mark

A normalization-based approach to the mobility analysis of spatial compliant multi-beam modules (2013)

Hao, Guangbo; Kong, Xianwen

Mark

A novel and miniaturized 433/868MHz multi-band wireless sensor platform for body sensor network applications (2012)

Buckley, John; O'Flynn, Brendan; Loizou, Loizos; Haigh, Peter; Boyle, David; Angov...

Mark

A novel approach to challenging consensus in evaluations: The Agitation Workshop (2013)

McAvoy, John; Nagle, Tadhg; Sammon, David

Mark

A novel CE microchip with micro pillars column & double-L injection design for Capacitance Coupled Contactless Conductivity detection technology (2016)

Wang, Yineng; Messina, Walter; Cao, Xi; Hogan, Anna; van Zalen, Ed; Moore, Eric J.

Mark

A novel cold active esterase from a deep sea sponge Stelletta normani metagenomic library (2017)

Borchert, Erik; Selvin, Joseph; Kiran, Seghal G.; Jackson, Stephen A.; O'Gara, Fer...

Mark

A novel erythromycin resistance plasmid from Bacillus sp strain HS24, isolated from the marine sponge Haliclona simulans (2014)

Barbosa, Teresa M.; Phelan, Robert W.; Leong, Dara; Morrissey, John P.; Adams, Claire; ...

Irish Research Council for Science Engineering and Technology

Mark

A novel method of microsatellite genotyping-by-sequencing using individual combinatorial barcoding (2016)

Vartia, Salla; Villanueva-Cañas, José L.; Finarelli, John; Farrell, Edward D.; Collins,...

Mark

A novel non-peptidic agonist of the ghrelin receptor with orexigenic activity in vivo (2016)

Pastor-Cavada, Elena; Pardo, Leticia M.; Kandil, Dalia; Torres-Fuentes, Cristina; Clark...

Mark

A novel process for mutation detection using uracil DNA-glycosylase (1998)

Vaughan, Patrick; McCarthy, Tommie V.

Mark

A paradigm shift in oxygen sensing with a twist in the tale! (2016)

O'Halloran, Ken D.

Mark

A passive circuit based RF optimization methodology for wireless sensor network nodes (2011)

Zheng, Liqiang; Mathewson, Alan; O'Flynn, Brendan; Hayes, Michael; Ó Mathúna, S. Cian

Mark

A phase II randomized clinical trial on cerebral near-infrared spectroscopy plus a treatment guideline versus treatment as usual for extremely preterm infants during the first three days of life (SafeBoosC): study protocol for a randomized controlled trial (2013)

Hyttel-Sorensen, Simon; Austin, Topun; van Bel, Frank; Benders, Manon; Claris, Olivier;...

Hyttel-Sorensen, Simon; Austin, Topun; van Bel, Frank; Benders, Manon; Claris, Olivier; Dempsey, Eugene M.; Fumagalli, Monica; Greisen, Gorm; Grevstad, Berit; Hagmann, Cornelia; Hellström-Westas, Lena; Lemmers, Petra; Lindschou, Jane; Naulaers, Gunnar; van Oeveren, Wim; Pellicer, Adelina; Pichler, Gerhard; Roll, Claudia; Skoog, Maria; Winkel, Per

Abstract:

Background: Every year in Europe about 25,000 infants are born extremely preterm. These infants have a 20% mortality rate, and 25% of survivors have severe long-term cerebral impairment. Preventative measures are key to reduce mortality and morbidity in an extremely preterm population. The primary objective of the SafeBoosC phase II trial is to examine if it is possible to stabilize the cerebral oxygenation of extremely preterm infants during the first 72 hours of life through the application of cerebral near-infrared spectroscopy (NIRS) oximetry and implementation of an clinical treatment guideline based on intervention thresholds of cerebral regional tissue saturation rStO2. Methods/Design: SafeBoosC is a randomized, blinded, multinational, phase II clinical trial. The inclusion criteria are: neonates born more than 12 weeks preterm; decision to conduct full life support; parental informed consent; and possibility to place the cerebral NIRS oximeter within 3 hours after birth. The...